Last edition
News about "pembrolizumab "
BerGenBio Begins Phase 2a in First Line NSCLC Patients with STK11m
BerGenBio ASA has initiated Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non-Small Cell Lung Cancer (NSCLC) patients
Pembrolizumab | 21/03/2024 | By Manvi | 223
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members